EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma

Overview of attention for article published in Medical Oncology, September 2017

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 7,849 followers.

RT @AlexDobrovic: Another outcome from#TGEG lab collaboration with our colleagues at St. V.'s and Peter Mac. #onjcri #Austin_Health https:/…

Another outcome from#TGEG lab collaboration with our colleagues at St. V.'s and Peter Mac. #onjcri #Austin_Health https://t.co/VpYbLbGQYE

Tim Clay: EGFR/KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in NSCLC… https://t.co/wqtKk19J3W

Pubmed: EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected… https://t.co/8PeE9NPz0l